Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Axitinib Versus Sunitinib Monotherapy in Participants with Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

Trial Identifier:	3475-426
Sponsor:	MSD
Start Date:	September 2016
Primary Completion Date:	October 2018
Study Completion Date:	December 2025
Condition:	Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language	Description
	Protocol Plain Language Summary - English

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.